These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34111149)

  • 1. Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer.
    Grassi T; Harris FR; Smadbeck JB; Murphy SJ; Block MS; Multinu F; Schaefer Klein JL; Zhang P; Karagouga G; Liu MC; Larish A; Lemens MA; Sommerfield MKS; Cappuccio S; Cheville JC; Vasmatzis G; Mariani A
    PLoS One; 2021; 16(6):e0252390. PubMed ID: 34111149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.
    Shintani D; Hihara T; Ogasawara A; Sato S; Yabuno A; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Int J Gynecol Cancer; 2020 Sep; 30(9):1340-1346. PubMed ID: 32699017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
    Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
    J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer.
    Kim YW; Kim YH; Song Y; Kim HS; Sim HW; Poojan S; Eom BW; Kook MC; Joo J; Hong KM
    Exp Mol Med; 2019 Aug; 51(8):1-10. PubMed ID: 31395853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma.
    Beinse G; Borghese B; Métairie M; Just PA; Poulet G; Garinet S; Parfait B; Didelot A; Bourreau C; Agueeff N; Lavollé A; Terris B; Chapron C; Goldwasser F; Leroy K; Blons H; Laurent-Puig P; Taly V; Alexandre J
    Clin Chem; 2022 Jun; 68(6):782-793. PubMed ID: 35323926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology.
    Muinelo-Romay L; Casas-Arozamena C; Abal M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30087246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers.
    Harris FR; Kovtun IV; Smadbeck J; Multinu F; Jatoi A; Kosari F; Kalli KR; Murphy SJ; Halling GC; Johnson SH; Liu MC; Mariani A; Vasmatzis G
    Sci Rep; 2016 Jul; 6():29831. PubMed ID: 27436510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
    Recio F; Scalise CB; Loar P; Lumish M; Berman T; Peddada A; Kalashnikova E; Rivero-Hinojosa S; Beisch T; Nicosia B; Farmer T; Dutta P; Malhotra M; ElNaggar AC; Liu MC; Vaccarello L; Holloway RW
    Gynecol Oncol; 2024 Mar; 182():63-69. PubMed ID: 38262240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    Cho MS; Park CH; Lee S; Park HS
    PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
    Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
    Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.
    Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M
    Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?
    Malentacchi F; Turrini I; Zepponi F; Fantappiè G; Sorbi F; Antonuzzo L; Fambrini M; Noci I; Pillozzi S
    Anticancer Drugs; 2020 Nov; 31(10):1091-1095. PubMed ID: 32568830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up.
    Relton A; Collins A; Guttery DS; Gorsia DN; McDermott HJ; Moss EL
    Eur J Cancer Care (Engl); 2021 Jul; 30(4):e13429. PubMed ID: 33616269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.